NASDAQ:TECH Bio-Techne Q1 2027 Earnings Results & Report $72.78 +0.12 (+0.17%) Closing price 04:00 PM EasternExtended Trading$72.79 +0.01 (+0.01%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Bio-Techne met analyst earnings expectations and beat on revenue in its Q1 2027 results, released November 6, 2026. The company reported EPS of $0.44 versus the $0.44 consensus estimate, while revenue of $299.71 million topped the $292.60 million estimate by $7.11 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2027Report DateNovember 6, 2026TimeBefore Market OpensConference Call4:00 PM ET Bio-Techne EPS ResultsActual EPS$0.44Consensus EPS $0.44Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersBio-Techne Revenue ResultsActual Revenue$299.71 millionExpected Revenue$292.60 millionBeat/MissBeat by +$7.11 millionYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Bio-Techne Q1 2027 Earnings FAQ Did Bio-Techne beat earnings estimates for Q1 2027? Bio-Techne (NASDAQ:TECH) reported earnings of $0.44 per share for Q1 2027, matching the consensus estimate of $0.44. The report was announced on Friday, November 6, 2026. What was Bio-Techne's revenue for Q1 2027? Bio-Techne reported revenue of $299.71 million for Q1 2027, against a consensus estimate of $292.60 million. Bio-Techne Earnings HeadlinesBio-Techne's $0.08 dividend hinges on Merck KGaA deal timing (NASDAQ: TECH)November 6 at 4:17 AM | americanbankingnews.comBio-Techne Corp (TECH) - What Are Researchers Thinking About This Stock?November 5 at 3:31 AM | americanbankingnews.comRIP AI. It’s over.AI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the big tech names pouring billions into data centers. Walmart's $24 million satellite network, AMR's Sabre system, and Capital One's 36,114 pricing tests all prove the same thing: compute has always been business's biggest moat, and it's about to get cheaper than ever. Porter Stansberry says one overlooked, government-protected sector is positioned to absorb this near-free compute boom and could become the next Magnificent 7.November 6 at 1:00 AM | Porter & Company (Ad)Bio-Techne (TECH), What Is Behind The Fresh Attention Now?November 4 at 5:04 PM | finance.yahoo.comBio-Techne Declares Dividend for the Quarter Ended September 30, 2026, Payable on November 23, 2026November 4 at 12:04 PM | marketscreener.comMBio-Techne declares $0.08 dividendNovember 4 at 1:57 AM | msn.comSee More Bio-Techne Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bio-Techne? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bio-Techne and other key companies, straight to your email. Email Address About Bio-TechneBio-Techne (NASDAQ:TECH)oration is a life sciences company that develops and supplies research and diagnostic products for biotechnology, pharmaceutical, academic, clinical and other laboratory customers. The company supports biological research, drug discovery and development, and diagnostic testing through a portfolio of reagents, instruments and analytical technologies. Its products include proteins, antibodies, immunoassays, flow cytometry reagents, molecular biology tools and cell culture materials. Bio-Techne also provides platforms for protein analysis, spatial biology, single-cell analysis, genomics and proteomics, as well as technologies used in cell and gene therapy development and manufacturing. The company traces its origins to Techne Corporation, which was founded in 1976, and adopted the Bio-Techne name in 2014. Its brands have included R&D Systems, ProteinSimple, Advanced Cell Diagnostics, Novus Biologicals and Tocris. Bio-Techne serves customers internationally through operations and distribution networks supporting research and clinical applications worldwide.View Bio-Techne ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?Riot's $28B Lease Shows Why Location and Contracts Matter in AICould the Midterms Revive Medicare for All? 3 Healthcare Stocks to WatchDuolingo's User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a CatchPowering Up: Freeport-McMoRan's $4.5B Copper Expansion Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
